1. Home
  2. ELTX vs LEE Comparison

ELTX vs LEE Comparison

Compare ELTX & LEE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Elicio Therapeutics Inc.

ELTX

Elicio Therapeutics Inc.

N/A

Current Price

$1.89

Market Cap

63.3M

Sector

Health Care

ML Signal

N/A

Logo Lee Enterprises Incorporated

LEE

Lee Enterprises Incorporated

N/A

Current Price

$7.51

Market Cap

152.5M

ML Signal

N/A

Company Overview

Basic Information
Metric
ELTX
LEE
Founded
2011
1890
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Newspapers/Magazines
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
63.3M
152.5M
IPO Year
2014
2025

Fundamental Metrics

Financial Performance
Metric
ELTX
LEE
Price
$1.89
$7.51
Analyst Decision
Buy
Analyst Count
4
0
Target Price
★ $13.67
N/A
AVG Volume (30 Days)
★ 304.4K
26.6K
Earning Date
11-12-2026
11-25-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 39.29
N/A
EPS
N/A
★ N/A
Revenue
$2,301,000.00
★ $543,955,000.00
Revenue This Year
N/A
$4.44
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$1.71
$3.34
52 Week High
$16.00
$11.88

Technical Indicators

Market Signals
Indicator
ELTX
LEE
Relative Strength Index (RSI) 35.13 53.80
Support Level $1.74 $7.29
Resistance Level $1.97 $8.79
Average True Range (ATR) 0.11 0.36
MACD 0.05 0.10
Stochastic Oscillator 55.77 88.24

Price Performance

Historical Comparison
ELTX
LEE

About ELTX Elicio Therapeutics Inc.

Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.

About LEE Lee Enterprises Incorporated

Lee Enterprises Inc is a local news publication company in the United States. It is a digital-first subscription business providing local markets with valuable, high-quality, trusted, intensely local news, information, advertising, and marketing services. The product portfolio of the company includes digital subscription platforms, daily, weekly, and monthly newspapers, and niche products, all delivering original local news and information as well as national and international news. The products offer digital and print editions, and content and advertising are available in real-time through the websites and mobile apps.

Share on Social Networks: